European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact

EMUC20: Highlights in GU cancers

Active surveillance should be considered the first treatment for prostate cancer in order to ensure the best quality of life.

Fri, 13 Nov 2020
OncologyProstate CancerEMUC 20Active SurveillanceEUPROMS StudyGenitourinary Pathology Society GUPSEMUC

Active surveillance should be considered the first treatment for prostate cancer in order to ensure the best quality of life. This was one of the key messages of Mr. André Deschamps’ (BE) presentation during the “Highlights in GU cancers” session on the first day of the 12th European Multidisciplinary Congress on Urological Cancers (EMUC20 Virtual). Mr. Deschamps presented the results of the EUPROMS study, a Patient-Reported Outcomes (PRO) study conducted by the patient advocacy organisation Europa Uomo.

The EUPROMS results revealed that active surveillance had the best average Expanded Prostate Cancer Index Composite (EPIC) score in incontinence (100) and sexual function (57). Respondents, 2943 prostate cancer patients from 24 European countries who received treatment, also experienced less tiredness, insomnia, and pain or discomfort while under active surveillance in comparison with other treatments. This led to Mr. Deschamps’ logical conclusion: “When it can be applied safely, active surveillance should be considered the first treatment for prostate cancer.”

During the discussion, via the interactive feature of the congress platform, Mr. Deschamps received two questions about the difference between the EUPROMS study and a clinical study. “It is a different kind of survey that we did. We wanted to have a picture of what the real quality of life of men is after treatment,” he clarified. “I think that clinical studies should be taking the quality of life into account as well: as a primary endpoint, in fact. Of course, it is also important to consider life extension when deciding to spend a lot of money on a new drug, but quality of life should always be an endpoint, too.”

In the same session, Prof. Jonathan Epstein (US) addressed the controversies and uncertainty that persist in prostate cancer grading and the first prostate cancer grading recommendations from the Genitourinary Pathology Society (GUPS) that focuses on these areas. Prof. Anders Bjartell (SE), chairman of the EAU Research Foundation (EAU RF), gave an update on the EAU RF trials in progress such as the PEGASUS study. He also touched on the PRECISION study, which became a game-changing trial showing the value of MRI before a prostate biopsy. The Nimbus study, which was stopped early due to safety reasons, was further discussed in the later session “New trials update.”

This session on GU cancer highlights was only one of the highlights of EMUC20 Virtual‘s first day. Covering a broad spectrum of topics in genitourinary malignancies, EMUC20 Virtual features speakers from all over the world. Unique about this first day was, characteristic of the year 2020, the roundtable about the impact of the Covid-19 epidemic on the management of GU cancers.

(Re)watch a session? All sessions are available on-demand in the Resource Centre.

Enlarge image

Share this article

Suggested for you

See all
About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer